The estimated Net Worth of Carman Alenson is at least $521 ezer dollars as of 21 June 2021. Carman Alenson owns over 1,777 units of Agios Pharmaceuticals Inc stock worth over $78,739 and over the last 8 years Carman sold AGIO stock worth over $441,835.
Carman has made over 15 trades of the Agios Pharmaceuticals Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently Carman exercised 1,777 units of AGIO stock worth $91,533 on 21 June 2021.
The largest trade Carman's ever made was exercising 3,590 units of Agios Pharmaceuticals Inc stock on 14 February 2020 worth over $159,073. On average, Carman trades about 822 units every 52 days since 2016. As of 21 June 2021 Carman still owns at least 1,777 units of Agios Pharmaceuticals Inc stock.
You can see the complete history of Carman Alenson stock trades at the bottom of the page.
Carman's mailing address filed with the SEC is C/O AGIOS PHARMACEUTICALS INC., 88 SIDNEY STREET, CAMBRIDGE, MA, 02139.
Over the last 11 years, insiders at Agios Pharmaceuticals Inc have traded over $77,887,085 worth of Agios Pharmaceuticals Inc stock and bought 3,229,562 units worth $154,554,190 . The most active insiders traders include Kevin P Starr, Robert Nelsen és John Maraganore. On average, Agios Pharmaceuticals Inc executives and independent directors trade stock every 9 days with the average trade being worth of $765,588. The most recent stock trade was executed by Rahul D. Ballal on 11 August 2024, trading 2,302 units of AGIO stock currently worth $102,002.
at agios, we are doing incredibly important and difficult work. we are trying to discover and develop breakthrough medicines, and we have a clear motivator — people with cancer and rare genetic diseases who are counting on us to be successful. we are a science-driven research organization. we have built a discovery platform upon our expertise in the fields of cellular metabolism and precision medicine across three major focus areas: cancer metabolism, rare genetic metabolic disorders and metabolic immuno-oncology. it takes people with a diversity of thought, skills, passions and backgrounds to get us from the first stages of understanding new biology and discovering drugs to our ultimate goal of getting these medicines to patients who are waiting for them. our connection to one another and our work and our commitment to our values enable us to potentially change the practice of medicine by by striving for excellence and doing things differently. we call this the "other side of possible
Agios Pharmaceuticals Inc executives and other stock owners filed with the SEC include: